Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 17, 2026
TickeronGET DAILY SIGNALS
Why Is Twist Bioscience (TWST) Stock Up +6.00% Today?

Why Is Twist Bioscience (TWST) Stock Up +6.00% Today?

Key Takeaways

  • Twist Bioscience (TWST) climbed 6.00%, or $6.30, to $111.34, recovering part of a 14% slide over the prior three sessions.
  • The primary catalyst was management's appearance at the Jefferies Global Healthcare Conference in London, where CEO Emily Leproust and CFO Adam Laponis reframed the fiscal 2027 outlook as capacity-limited rather than demand-limited.
  • Management reiterated that AI-driven drug discovery revenue should reach at least $100 million in fiscal 2027, up from $59 million in fiscal 2026 and $21 million in fiscal 2025.
  • Secondary driver: an oversold bounce after target cuts from Barclays, Baird, Leerink, TD Cowen, Guggenheim and UBS following the November 12 earnings report.
  • Broader context: the move was entirely company-specific, with the Nasdaq-100 proxy down about 1.3% and biotech benchmarks slightly lower on the day.
  • News Significance Score: 16/100 — modest conference-driven reassurance against a move only about 1.2 times the stock's typical daily swing.
  • Traders are watching whether the $105 area holds as support, whether volume expands on further gains, and the December 1 Evercore healthcare fireside chat.
  • For deeper detail on Price Targets, Earnings, and Forecast data, explore the dedicated Tickeron pages for this ticker.
  • Explore Trending AI Robots to see which automated strategies are performing best in the current market.

Opening Summary

Twist Bioscience Corporation (TWST) is a South San Francisco–based synthetic biology company that writes DNA on silicon chips, supplying synthetic genes, oligo pools, antibody libraries and next-generation sequencing panels to pharmaceutical, biotech and academic customers, including a fast-growing AI drug discovery franchise. Shares closed the prior session at $105.04 and were last changing hands at $111.34, a gain of $6.30, or 6.00%, with the move confirmed as upward. The rebound was driven by management commentary at an investor conference that pushed back on the bearish read of last week's fiscal 2027 outlook, supported by bargain-hunting after a steep three-day decline.

Management Reframes the Fiscal 2027 Outlook

The decisive intraday turn came during the Jefferies Global Healthcare Conference fireside chat in London. Leadership walked investors through the AI drug discovery revenue curve: roughly $21 million in fiscal 2025, $59 million in fiscal 2026, and guidance of at least $100 million for fiscal 2027. Executives stressed that the difference between the formal guide and the potential for triple-digit percentage growth is a manufacturing capacity question, not a demand question, and pointed to roughly $150 million of capital spending across the next two years, including about $75 million in fiscal 2027, to add capacity. Comments also highlighted broadening demand across AI-native drug hunters and large pharma partners, and a shift toward more complex multi-domain antibody formats that consume more data and more synthesis. That framing directly addressed the concern that drove the stock sharply lower after the November 12 report.

Oversold Rebound After a Three-Session Slide

Twist had fallen 6.8% on November 12, 2.3% on November 13 and 5.9% on November 16, a cumulative decline of about 14%. Sell-side reaction added pressure, with price targets trimmed to $130 at Barclays, $135 at Baird, $175 at Leerink, $137 at TD Cowen, $150 at Guggenheim and $120 at UBS, even as most firms kept constructive ratings. With the stock roughly 49% below its October 6 high of $219.71 and well under its 20-day and 60-day moving averages, a snap-back was structurally likely once sellers were exhausted. The morning low near $102.82 marked the turning point.

Why the Move Stood Out From the Sector

Peer and benchmark action offered no tailwind. Genomics peer TXG gained about 2.6%, but diagnostics name TEM slipped roughly 1.9% and AI-drug-discovery peer RXRX fell nearly 7%. Broader indices were lower, with the S&P 500 down about 1.4% and the Nasdaq-100 proxy down about 1.3% in the final hour. Against that backdrop, Twist's gain was an idiosyncratic, single-name event rather than sector sympathy, and it occurred despite an overhang from an early-November short-seller report questioning valuation and from disclosure of executive share sales that has kept sentiment on edge.

Market Context and Trading Activity

Volume was not the story. Turnover tracked near the 60-session average of roughly 1.3 million shares, meaning the advance was achieved without a notable surge in participation — consistent with short covering and dip-buying rather than a fundamental re-rating. The stock recaptured the $105 level that had capped Monday's close and pushed back above $110, a short-term technical repair that leaves it still far below its November 12 opening gap. Market capitalization stands at approximately $7.3 billion.

News Significance Score

The scale runs from 0 — no meaningful news and a routine move for the stock — to 100, meaning transformative news plus an extreme, rare price move. Twist scores 16 out of 100. The verified news was moderate at best: no new filing, contract or earnings release, only management restating and contextualizing guidance it issued days earlier at a conference. The price action was unremarkable by the stock's own standards, at roughly 1.2 times its typical daily move of about 5%, and moves of 6% or more occurred 19 times in the last 60 sessions. Weak news and a very ordinary swing for this name combine into a low score.

What Comes Next for TWST

Attention shifts to fiscal first-quarter 2027 results, expected in early February, and the December 1 Evercore Healthcare Conference fireside chat, where investors will look for more precision on capacity additions and AI drug discovery bookings. Key variables include the pacing of revenue conversion toward the $100 million target, gross margin trajectory after fiscal 2026's 52.4%, and whether adjusted EBITDA remains positive following the $2.2 million posted in the fourth quarter. Risks include customer concentration among a small set of AI-native buyers, capital intensity of the expansion, lingering valuation debate, and the possibility that capacity ramp timelines slip. Analyst consensus remains a Buy with an average target near $129, though the wide spread between the $45 low and $175 high underscores how divided the Street is on this name.

Trending AI Robots

Tickeron provides hundreds of AI trading bots that cover thousands of tickers, but the Trending AI Robots page features only the strongest performers under current market conditions. Bots differ by strategy, timeframe, performance metrics, and the symbols they trade, so the curated list offers a practical starting point for matching a model to your own approach. Review the live rankings to see which automated strategies are keeping pace with today's volatile tape.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: TWST

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


TWST sees MACD Histogram crosses below signal line

TWST saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 02, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 44 instances where the indicator turned negative. In 42 of the 44 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TWST as a result. In 61 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.

TWST moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for TWST crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TWST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

TWST broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for TWST entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +10.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where TWST advanced for three days, in 235 of 291 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.967) is normal, around the industry mean (3.592). P/E Ratio (-54.166) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (20.243) is also within normal values, averaging (442.120).

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. TWST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 86 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TWST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -5%. For the same Industry, the average monthly price growth was -12%, and the average quarterly price growth was -25%. SLS experienced the highest price growth at 113%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 19%. For the same stocks of the Industry, the average monthly volume growth was -10% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
Real Time Patterns 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of proprietary semiconductor-based synthetic DNA manufacturing process

Industry Biotechnology

Industry
Biotechnology
Address
681 Gateway Boulevard
Phone
+1 800 719-0671
Employees
979
Web
https://www.twistbioscience.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.
KLAR dropped -4.84% to $13.75 from Wednesday's close of $14.45, with the decline occurring during Thursday's regular session. JPMorgan downgraded the shares to Hold from Overweight and cut its price target to $17 from $20 in a note published before the open, extending a run of post-earnings target reductions.